Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)

摘要: CRA4027 Background: Pmab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved as monotherapy in US for mCRC following disease progression (PD) and EU Canada tumors bearing wild-type (WT) KRAS. The most common toxicity with anti-EGFR inhibitors are ST. This study of pmab+ chemotherapy (CT) estimates difference incidence specific ≥ grade 2 ST interest between pts receiving prophylactic (P) or reactive (R) skin tx. Methods: Pts had unresectable after PD 1st-line fluoropyrimidine oxaliplatin-based CT ± bevacizumab. received either pmab 6.0mg/kg/FOLFIRI Q2W 9 mg/kg/irinotecan Q3W. Within each stratum, were randomized 1:1 to P tx 24 hrs before 1st dose daily 6 wks R occurred. Tx included: moisturizers, sunscreen, topical steroid, doxycycline. Efficacy safety evaluated by vs groups, KRAS status (mutant [MT] WT), statu...